Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
|Poll|July 11, 2016
Mini Quiz: Physicians as Patients
Author(s)Penelope P. Ziegler, MD
When physicians behave disruptively in the workplace, what is the most likely cause?
Advertisement
Physicians who behave disruptively in the workplace are most commonly suffering from:
Advertisement
Related to this article
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Cannabis Use Prevalent In Substance-Related Adolescent Emergency Care: Insights From Kevin Xu, MD
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
4
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
5